MicroSense International, LLC Announces Key Addition to Clinical Advisory Board

Monday,January 27, 2014 @ 00:47

(PRWEB) September 27, 2002

MicroSense International, LLC Announces Key Addition to Clinical Advisory Board

Edward S. Horton, MD, Director for Clinical Research for the Joslin Diabetes Center, Boston, Agrees to Serve on Clinical Advisory Board

FOR IMMEDIATE RELEASE: September 23, 2002/St. Louis, MO/ MicroSense International, LLC (http://www.micro-sense.com), a development stage privately funded medical device company today announced that Edward S. Horton, MD, Director for Clinical Research at the Joslin Diabetes Center, Boston has agreed to serve on the Clinical Advisory Board for MicroSense. The Joslin Diabetes Center is an Affiliate of Harvard Medical School.

William Edelman, Chairman & CEO for MicroSense commented, “We are thrilled to collaborate with a physician of Dr. Horton’s reputation and background in the field of diabetes research and care.” Mr. Edelman continued, “With 40 years experience in the field of diabetes, over 100 articles published and having authored 3 books in this area, Dr. Horton contributes a unique capability to our efforts in the diabetes field.”

Mr. Edelman continued, “ MicroSense is committed to bringing the Pushita(TM) micro-invasive glucose measurement system to market. The Pushita(TM) system is both bloodless and painless, and has successfully been employed in 36 Type I and Type II diabetic patients for the measurement of glucose levels, critical for the management of diabetes. The device consists of a single-use disposable opto/enzyme probe and a multi-use meter. The device measures glucose levels in the interstitial space. Glucose data measured by Pushita(TM) in this first series of patients compared favorably to multiple control measurements taken by commercially available glucose meters.”

Current glucose detection technology requires blood samples in order to determine the concentration of glucose. Pushita(TM) measurements are painless and do not require the lancing of the finger, a painful procedure required by patients to provide a blood sample for measurement. By measuring the interstitial fluid at the forefinger, Pushita(TM) is intended to address reported glucose measurement deficiencies in currently available blood glucose meters, which rely on measurements from sites other than the forefinger (“alternate sites”).

William Edelman, Chairman and CEO for MicroSense, stated, “Each step we take helps to further demonstrate the value of this technology and enable us to differentiate Pushita(TM) from existing glucose devices. Our main advantages address the universal issues faced by diabetics today, namely blood required for glucose measurement and pain associated with the repeated ritual of sampling glucose levels. By offering an effective blood-free and painless alternative to blood glucose systems, we hope to create a value proposition highly regarded by the financial markets, and the consumer population.”

According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK.), over15.7 million people, 5.9 percent of the population has diabetes. Of that number, 10.3 million people have had a diagnosis of either Type 1 or Type 2 diabetes, and 5.4 million people are undiagnosed. There are over 798,000 new cases diagnosed annually. The total domestic cost of diabetes (both direct and indirect) exceeds $ 100 billion annually, attributed to disability, work loss, and premature mortality.

About MicroSense International, LLC

Founded in 1997, MicroSense International, LLC, is a development stage, privately funded medical device company developing painless and bloodless techniques for the measurement of important biological markers for the management of chronic diseases. The company has development faculties in St. Louis, MO, and offices in Boston, MA.

Pushita(TM) measures biological markers present in the interstitial fluid (ISF). MicroSense has targeted several large chronic disease populations requiring constant spot monitoring, including diabetes, congestive heart failure (CHF), and kidney disease.

Statements in this news release looking forward in time are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties, including general economic conditions, delays and risks associated with the performance of contracts, uncertainties as a result of research and development, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, and regulatory risks including approval of pending and/or contemplated 510(k) and PMA filings.

About Joslin Diabetes Center

Established in 1898, Joslin Diabetes Center is an internationally recognized diabetes treatment, research and education institution affiliated with Harvard Medical School and headquartered in Boston, MA. Joslin is a non-profit organization dedicated to finding a cure for diabetes and improving the lives of people with diabetes through its cutting edge basic and clinical research, patient care programs for children and adults, and through programs and publications that improve the care of diabetes worldwide. Some of the most important improvements in diabetes care — including treatments for diabetes in pregnancy, the development of laser surgery to treat diabetic eye disease, and the identification of markers for “pre-diabetes” — were developed at Joslin. In addition to its headquarters facility in Boston, Joslin has affiliated treatment facilities at more than 25 locations from coast to coast.

For further information, please contact William Edelman, Chairman & CEO (wedelman@micro-sense.com), MicroSense International, LLC, 4041 Forest Park Avenue, St. Louis, MO 63108, (314) 615-6969 office, and (314) 615-6324 facsimile.

Previous post:

Next post: